Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Seasonique

Teva Pharma logo

Teva says chronic migraine drug is ready for phase III

TEV-48125 efficacy “has not previously been achieved”

EU flag

Mid-sized European biotechs ‘need more support’

New report finds that the industry is fairing better in the US than in the EU

- PMLiVE

Perrigo rejects Mylan again as Teva bites back

There is much debate over the value of the company’s shares

- PMLiVE

Mylan pulls no punches in rejecting Teva takeover

Firm calls Israeli generics giant’s credibility into question

- PMLiVE

Teva circling as Perrigo rejects second Mylan offer

Claims latest offer is lower than a recent informal bid

- PMLiVE

Teva offers $40bn for Mylan as Perrigo backs away

Generic drug industry could be shaken up if deals go through

Teva Pharma logo

Teva slapped with $512m fine on pay-for-delay deal

Israeli firm pays out to settle claims it hindered use of generic Provigil

Teva Pharma logo

Teva starts M&A push with $3.5bn Auspex buy

Aims to diversify business away from dependency on Copaxone

- PMLiVE

WHO: Medicine costs ‘too high’ for European governments

New report shows transparency and co-operation needed to help reduce drug prices

Teva appoints Timothy Wright as business development head

The former Covidien Pharma president mostrecently led a US cancer centre

EU flag

Half a million cancer patients in EU use targeted drugs

New data also shows breast and lung cancers are among the most treated in Europe

Sanofi reception

Generic competition for Sanofi’s Renvela hits UK market

Teva and others launch cheaper versions of the chronic kidney disease drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links